The results showed that in the low-dose anti-VEGFR2 antibody (DC101) group, the MFI of LAYN significantly decreased in tumor-infiltrating exhausted CD8+T cells (Fig. 3a), but the percentage of T cells treated by combination of different dosage of DC101 with anti-PD1 antibody in vitro didn’t change (Fig. S7). The gene discussed is CD8A; the disease is neoplasm.